JP6663854B2 - 代謝が最適化された細胞培養 - Google Patents

代謝が最適化された細胞培養 Download PDF

Info

Publication number
JP6663854B2
JP6663854B2 JP2016547976A JP2016547976A JP6663854B2 JP 6663854 B2 JP6663854 B2 JP 6663854B2 JP 2016547976 A JP2016547976 A JP 2016547976A JP 2016547976 A JP2016547976 A JP 2016547976A JP 6663854 B2 JP6663854 B2 JP 6663854B2
Authority
JP
Japan
Prior art keywords
cells
cell culture
cell
culture
lactate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016547976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532457A5 (enExample
JP2016532457A (ja
Inventor
ショーン ローレンス，
ショーン ローレンス，
アン キム，
アン キム，
エイミー ジョンソン，
エイミー ジョンソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6663854(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2016532457A publication Critical patent/JP2016532457A/ja
Publication of JP2016532457A5 publication Critical patent/JP2016532457A5/ja
Priority to JP2020024484A priority Critical patent/JP6967620B2/ja
Application granted granted Critical
Publication of JP6663854B2 publication Critical patent/JP6663854B2/ja
Priority to JP2021173755A priority patent/JP7377243B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
JP2016547976A 2013-10-11 2014-10-10 代謝が最適化された細胞培養 Active JP6663854B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020024484A JP6967620B2 (ja) 2013-10-11 2020-02-17 代謝が最適化された細胞培養
JP2021173755A JP7377243B2 (ja) 2013-10-11 2021-10-25 代謝が最適化された細胞培養

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361889815P 2013-10-11 2013-10-11
US61/889,815 2013-10-11
PCT/US2014/059993 WO2015054554A1 (en) 2013-10-11 2014-10-10 Metabolically optimized cell culture

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020024484A Division JP6967620B2 (ja) 2013-10-11 2020-02-17 代謝が最適化された細胞培養

Publications (3)

Publication Number Publication Date
JP2016532457A JP2016532457A (ja) 2016-10-20
JP2016532457A5 JP2016532457A5 (enExample) 2017-11-09
JP6663854B2 true JP6663854B2 (ja) 2020-03-13

Family

ID=52813657

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016547976A Active JP6663854B2 (ja) 2013-10-11 2014-10-10 代謝が最適化された細胞培養
JP2020024484A Active JP6967620B2 (ja) 2013-10-11 2020-02-17 代謝が最適化された細胞培養
JP2021173755A Active JP7377243B2 (ja) 2013-10-11 2021-10-25 代謝が最適化された細胞培養

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020024484A Active JP6967620B2 (ja) 2013-10-11 2020-02-17 代謝が最適化された細胞培養
JP2021173755A Active JP7377243B2 (ja) 2013-10-11 2021-10-25 代謝が最適化された細胞培養

Country Status (17)

Country Link
US (2) US20160244725A1 (enExample)
EP (3) EP3351620B1 (enExample)
JP (3) JP6663854B2 (enExample)
KR (4) KR102358807B1 (enExample)
CN (2) CN114717196A (enExample)
AU (2) AU2014331776B2 (enExample)
CA (1) CA2926049C (enExample)
DK (2) DK3055409T3 (enExample)
EA (2) EA033783B1 (enExample)
ES (2) ES2833471T3 (enExample)
HU (2) HUE051049T2 (enExample)
IL (2) IL244511A0 (enExample)
MX (2) MX376623B (enExample)
PL (2) PL3055409T3 (enExample)
SG (2) SG10201800772TA (enExample)
WO (1) WO2015054554A1 (enExample)
ZA (1) ZA201601550B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2833471T3 (es) 2013-10-11 2021-06-15 Regeneron Pharma Cultivo celular metabólicamente optimizado
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US20160244726A1 (en) * 2013-10-11 2016-08-25 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
JP7260018B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260011B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260020B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7310947B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7272480B2 (ja) * 2017-04-27 2023-05-12 株式会社三洋物産 遊技機
JP7310952B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7260021B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7310945B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7260009B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7260012B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7260013B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7323512B2 (ja) 2017-10-06 2023-08-08 ロンザ リミテッド ラマン分光法を使用する細胞培養の自動制御
EP4039786A1 (en) 2017-10-16 2022-08-10 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
EP3717656B1 (en) * 2017-11-30 2024-03-13 F. Hoffmann-La Roche AG Process for culturing mammalian cells
MX2020010028A (es) * 2018-03-29 2020-10-14 Genentech Inc Actividad lactogenica modulada en celulas de mamifero.
GB201810772D0 (en) * 2018-06-29 2018-08-15 Ge Healthcare Bio Sciences Ab Method in bioprocess purification system
JP7231355B2 (ja) * 2018-08-22 2023-03-01 日機装株式会社 細胞培養方法および細胞培養装置
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
JP2020151559A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
JP2020151560A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
EP3985097A1 (en) * 2020-10-14 2022-04-20 Sartorius Stedim Biotech GmbH A method and system for configuring and/or setup of a downstream process for processing a biomass

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6165741A (en) 1997-05-30 2000-12-26 The Trustees Of The University Of Pennsylvania Method for rapid detection of bacterial growth in cultures
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6919183B2 (en) 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US6953692B2 (en) * 2001-12-18 2005-10-11 Bayer Pharmaceuticals Corporation Device and method for seed-train expansion of mammalian cells
US7039770B1 (en) 2002-03-05 2006-05-02 Juniper Networks, Inc. Low latency request dispatcher
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
SI1623019T1 (sl) 2003-05-15 2010-10-29 Wyeth Llc Omejeno glukozno dovajanje za živalsko celično kulturo
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
CA2628340A1 (en) * 2005-11-02 2007-05-18 Wyeth Methods for adapting mammalian cells
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US7575890B2 (en) 2006-01-18 2009-08-18 Oxygen Enterprises, Ltd. Method for rapid detection and evaluation of cultured cell growth
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
EP3327132A3 (en) 2007-08-09 2018-07-18 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
SI2331678T1 (sl) * 2008-06-13 2015-12-31 Janssen Biotech, Inc. Postopki za dobivanje visoke gostote viabilnih celic v sesalski celični kulturi
US8470552B2 (en) * 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
ES2533074T3 (es) * 2010-04-26 2015-04-07 Novartis Ag Medio de cultivo celular mejorado
RU2614125C2 (ru) * 2010-05-28 2017-03-22 Дженентек, Инк. Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы
TWI637057B (zh) 2012-11-09 2018-10-01 拜爾沙納有限公司 具交替生物反應器用途之不連續進料批次製程
WO2014109858A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
ES2833471T3 (es) 2013-10-11 2021-06-15 Regeneron Pharma Cultivo celular metabólicamente optimizado

Also Published As

Publication number Publication date
JP2022009453A (ja) 2022-01-14
MX2016004564A (es) 2016-07-12
AU2021200193B2 (en) 2023-08-24
HK1223122A1 (en) 2017-07-21
EP3055409A1 (en) 2016-08-17
EP3055409A4 (en) 2016-09-28
EA033783B1 (ru) 2019-11-25
AU2021200193A1 (en) 2021-03-18
CN105637085A (zh) 2016-06-01
US20210087535A1 (en) 2021-03-25
ES2678945T3 (es) 2018-08-21
ZA201601550B (en) 2023-05-31
CA2926049A1 (en) 2015-04-16
PL3055409T3 (pl) 2018-10-31
MX2020011334A (es) 2021-07-30
CN114717196A (zh) 2022-07-08
EA201991976A1 (ru) 2020-04-02
MX384960B (es) 2025-03-14
JP6967620B2 (ja) 2021-11-17
DK3351620T3 (da) 2020-10-26
JP2016532457A (ja) 2016-10-20
AU2014331776A1 (en) 2016-03-24
KR20230038324A (ko) 2023-03-17
KR102510238B1 (ko) 2023-03-16
EP3812453A1 (en) 2021-04-28
SG10201800772TA (en) 2018-03-28
KR20220020415A (ko) 2022-02-18
KR20210046835A (ko) 2021-04-28
SG11201601681QA (en) 2016-04-28
EP3055409B1 (en) 2018-04-25
HUE039551T2 (hu) 2019-01-28
HK1253275A1 (en) 2019-06-14
IL244511A0 (en) 2016-04-21
EP3351620A1 (en) 2018-07-25
KR20160062032A (ko) 2016-06-01
JP2020072760A (ja) 2020-05-14
WO2015054554A1 (en) 2015-04-16
ES2833471T3 (es) 2021-06-15
KR102358807B1 (ko) 2022-02-08
KR102610425B1 (ko) 2023-12-06
HUE051049T2 (hu) 2021-01-28
US20160244725A1 (en) 2016-08-25
DK3055409T3 (en) 2018-07-30
JP7377243B2 (ja) 2023-11-09
PL3351620T3 (pl) 2021-03-08
CA2926049C (en) 2023-09-05
EA201690600A1 (ru) 2016-09-30
KR102243980B1 (ko) 2021-04-26
EP3351620B1 (en) 2020-09-02
MX376623B (es) 2025-03-07
AU2014331776B2 (en) 2020-10-22
IL262833A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
JP7377243B2 (ja) 代謝が最適化された細胞培養
US20250326820A1 (en) Metabolically optimized cell culture
US20160244726A1 (en) Metabolically optimized cell culture
HK40042432A (en) Metabolically optimized cell culture
HK1253275B (en) Metabolically optimized cell culture
HK1223122B (en) Metabolically optimized cell culture
EA040764B1 (ru) Метаболически оптимизированная клеточная культура
BR122024020665A2 (pt) Método para cultivar células, e, célula hospedeira metabolicamente alterada
BR122024020669A2 (pt) Método para cultivar células, e, célula hospedeira metabolicamente alterada
BR112016007739B1 (pt) Método para cultivar células
EA045030B1 (ru) Метаболически оптимизированная клеточная культура

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190320

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200217

R150 Certificate of patent or registration of utility model

Ref document number: 6663854

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250